Image
Mini-Curriculum

Updates in Autoimmunity and Chronic Inflammatory Disorders

Think You Know JAK?

RA Guidelines

2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.

Singh JA, et al. Arthritis Rheumatol. 2016;68(1):1-26.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, et al. Ann Rheum Dis. 2013;72(4):482-492.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, et al. Ann Rheum Dis. 2017;76(6):960-977.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS, et al. Ann Rheum Dis. 2016;75(1):3-15.

IBD Guidelines

ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Lichtenstein GR, et al. Am J Gastroenterol. 2018;113:481-517.

Ulcerative Colitis Care Pathway.

Dassopoulos T, et al. Gastroenterology. 2015;149(1):238-245.

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Peyrin-Biroulet L, et al. Am J Gastroenterol. 2015;110(9):1324-1338.

European Crohn’s and Colitis Organisation

RA Patient and Provider Resources

American College of Rheumatology Disease Overview

The American College of Rheumatology has published a concise overview to help patients and caregivers learn more about rheumatoid arthritis and to provide tips for living well with this rheumatic disease.

American College of Rheumatology Patient Education Videos

The American College of Rheumatology has produced a library of videos about the impact of rheumatic disease, what to do when diagnosed with rheumatic disease, when to see a rheumatologist, and what patients have to say about their experiences of living with rheumatic disease.

Arthritis Foundation

The Arthritis Foundation provides self-care tools and resources covering treatment options, pain management, diet and exercise, and common comorbidities associated with many different arthritic conditions.

EULAR ‘Don’t Delay, Connect Today’ Campaign

This European League Against Rheumatism (EULAR) Campaign aims to raise awareness of the importance of early diagnosis in preventing further damage to those living with rheumatic and musculoskeletal diseases, and to encourage timely access to evidence-based treatment.

European League Against Rheumatism

EULAR is an organization that represents people with arthritis/rheumatism, health professionals, and scientific societies of rheumatology of all the European nations. 

Health Topics: Rheumatoid Arthritis

A resource from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about this disease. 

Rheumatoid Arthritis Support Network

The Rheumatoid Arthritis Support Network provides up-to-date information for patients with rheumatoid arthritis, including links to patient support groups, blogs written by patients with rheumatoid arthritis, resources to help pay for medications, and smart device apps to help track symptoms over time.

IBD Patient Resources

Inflammatory Bowel Disease (IBD): What Is It?

Crohn’s and Colitis Foundation

Types of Medications for Crohn’s Disease and Ulcerative Colitis

Treatment Decisions

Advocacy Tools and Resources

Crohn’s Disease and Ulcerative Colitis: Emotional Factors Q & A

The National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center

Crohn’s Disease

Ulcerative Colitis

RA Suggested Readings

Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies.

Fleischmann R, et al. RMD Open. 2017;3(2):e000491.

Upadacitinib (ABT-494) in patients with active rheumatoid arthritis and inadequate response or intolerance to biological DMARDs: a phase 3 randomized, placebo-controlled, double-blind study of a selective JAK-1 inhibitor.

Genovese MC, et al. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 10L.

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).

Westhovens R, et al. Ann Rheum Dis. 2017;76(6):998-1008.

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).

Kavanaugh A, et al. Ann Rheum Dis. 2017;76(6):1009-1019.

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.

Genovese MC, et al. Rheumatology. 2018;57(5):900-908.

Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk?

Scott IC, et al. Drug Saf. 2018;41(7):645-653.

IBD Suggested Readings

Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Colombel JF, et al. Lancet. 2018;390(10114):2779-2789.

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

Coskun M, et al. Pharmacol Res. 2013;76:1-8.

Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies.

Kim DH, et al. Immune Netw. 2017;11(1):25-40.

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.

De Vries LCS, et al. J Crohns Colitis. 2017;11(7):885-893.

JAK inhibition in inflammatory bowel disease.

Olivera P, et al. Expert Rev Clin Immunol. 2017;13:693-703.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Sandborn WJ, et al. N Engl J Med. 2017;377(5):496-497.

Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

Vermeire S, et al. Lancet. 2017;389(10066):266-275.

Activity
JAK-STAT Signaling and Disease Pathogenesis in RA and IBD

Module 1

Activity
JAK Inhibition in Inflammatory Bowel Disease

Module 2

Activity
JAK Inhibition in Rheumatoid Arthritis

Module 3

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances